115 related articles for article (PubMed ID: 26918251)
1. Authors’ reply.
Goláň L; Chang P
Drug Des Devel Ther; 2015; 9():5875. PubMed ID: 26918251
[No Abstract] [Full Text] [Related]
2. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy was underpowered.
Ortiz A; Sanchez-Niño MD
Drug Des Devel Ther; 2015; 9():5873-4. PubMed ID: 26586938
[No Abstract] [Full Text] [Related]
3. Disease progress in patients with Morbus Fabry after switching from agalsidase beta to agalsidase alpha.
Reidt S; Namdar M; Serra A; Krayenbühl PA; Gruner C; Keller DI; Lüscher TF; Schmied C
Intern Med J; 2014 Feb; 44(2):205-7. PubMed ID: 24528819
[No Abstract] [Full Text] [Related]
4. Ultrastructural Evidence of Glycosphingolipid Degradation After Enzyme Replacement Therapy in Patients With Fabry Disease.
Onoue K; Takemura G; Nakano T; Miyazaki N; Tsujimoto A; Watanabe T; Okada H; Kanamori H; Sugiura J; Kanaoka K; Ishihara S; Horii M; Akai Y; Sakaguchi Y; Saito Y
Circ J; 2019 Sep; 83(10):2081. PubMed ID: 30930427
[No Abstract] [Full Text] [Related]
5. [Treatment of Fabry disease: Successes, failures, and expectations].
Lidove O; Barbey F; Joly D
Nephrol Ther; 2016 Apr; 12 Suppl 1():S105-13. PubMed ID: 26968478
[TBL] [Abstract][Full Text] [Related]
6. Anderson Fabry disease: a multiorgan metabolic disease susceptible of treatment.
Tuttolomondo A
Curr Pharm Des; 2013; 19(33):5972-3. PubMed ID: 23448458
[No Abstract] [Full Text] [Related]
7. Prominent regression of corneal deposits in Fabry disease 16 years after initiation of enzyme replacement therapy.
Koh S; Sakai N; Maeda N; Nishida K
Acta Ophthalmol; 2018 Mar; 96(2):e255-e256. PubMed ID: 28834375
[No Abstract] [Full Text] [Related]
8. Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?
Fauchais AL; Prey S; Ouatara B; Vidal E; Sparsa A
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):737-8. PubMed ID: 19925601
[No Abstract] [Full Text] [Related]
9. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
Senocak Tasci E; Bicik Z
Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
[TBL] [Abstract][Full Text] [Related]
10. Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion.
Lenders M; Schmitz B; Brand SM; Foell D; Brand E
J Allergy Clin Immunol; 2018 Jun; 141(6):2289-2292.e7. PubMed ID: 29421273
[No Abstract] [Full Text] [Related]
11. Neutralizing anti-drug antibodies in Fabry disease have no obvious clinical impact?
Lenders M; Schmitz B; Brand SM; Brand E
Orphanet J Rare Dis; 2018 Sep; 13(1):171. PubMed ID: 30268124
[TBL] [Abstract][Full Text] [Related]
12. Safety of switching to Migalastat from enzyme replacement therapy in Fabry disease: Experience from the Phase 3 ATTRACT study.
Hughes DA; Nicholls K; Sunder-Plassmann G; Jovanovic A; Feldt-Rasmussen U; Schiffmann R; Giugliani R; Jain V; Viereck C; Castelli JP; Skuban N; Barth JA; Bichet DG
Am J Med Genet A; 2019 Jun; 179(6):1069-1073. PubMed ID: 30920142
[No Abstract] [Full Text] [Related]
13. Improved Efficacy in a Fabry Disease Model Using a Systemic mRNA Liver Depot System as Compared to Enzyme Replacement Therapy.
DeRosa F; Smith L; Shen Y; Huang Y; Pan J; Xie H; Yahalom B; Heartlein MW
Mol Ther; 2019 Apr; 27(4):878-889. PubMed ID: 30879951
[TBL] [Abstract][Full Text] [Related]
14. Bioevaluation of sixteen ADMDP stereoisomers toward alpha-galactosidase A: Development of a new pharmacological chaperone for the treatment of Fabry disease and potential enhancement of enzyme replacement therapy efficiency.
Cheng WC; Wang JH; Li HY; Lu SJ; Hu JM; Yun WY; Chiu CH; Yang WB; Chien YH; Hwu WL
Eur J Med Chem; 2016 Nov; 123():14-20. PubMed ID: 27474919
[TBL] [Abstract][Full Text] [Related]
15. Fabry disease manifesting as chronic uveitis--treated with enzyme replacement therapy.
Shen YD; Yang CM; Huang JS
Eye (Lond); 2007 Mar; 21(3):431-2. PubMed ID: 16858434
[No Abstract] [Full Text] [Related]
16. Fabry disease: kidney involvement and enzyme replacement therapy.
Siamopoulos KC
Kidney Int; 2004 Feb; 65(2):744-53. PubMed ID: 14717955
[No Abstract] [Full Text] [Related]
17. Surges in proteinuria are associated with plasma GL-3 elevations in a young patient with classic Fabry disease.
Kanai T; Ito T; Odaka J; Saito T; Aoyagi J; Betsui H; Yamagata T
Eur J Pediatr; 2016 Mar; 175(3):427-31. PubMed ID: 26454753
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the efficacy and safety of three dosing regimens of agalsidase alfa enzyme replacement therapy in adults with Fabry disease.
Goláň L; Goker-Alpan O; Holida M; Kantola I; Klopotowski M; Kuusisto J; Linhart A; Musial J; Nicholls K; Gonzalez-Rodriguez D; Sharma R; Vujkovac B; Chang P; Wijatyk A
Drug Des Devel Ther; 2015; 9():3435-44. PubMed ID: 26185417
[TBL] [Abstract][Full Text] [Related]
19. Successful long-term enzyme replacement therapy in a young adult with Fabry disease.
Kampmann C; Kalkum G; Beck M; Whybra C
Clin Genet; 2013 Apr; 83(4):395-6. PubMed ID: 22881192
[No Abstract] [Full Text] [Related]
20. Searching for an additional treatment to slowing the progression of Fabry disease.
Ravarotto V; Carraro G; Simioni F; Bertoldi G; Pagnin E; Calò LA
Minerva Med; 2019 Apr; 110(2):176-178. PubMed ID: 30821433
[No Abstract] [Full Text] [Related]
[Next] [New Search]
